In Vitro Activities of Linezolid and Tigecycline Against Methicillin-Resistant Staphylococcus aureus Strains
- 1 June 2008
- journal article
- Published by Mary Ann Liebert Inc in Microbial Drug Resistance
- Vol. 14 (2), 151-153
- https://doi.org/10.1089/mdr.2008.0801
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a nosocomial pathogen that causes morbidity and mortality worldwide. The options for the treatment of MRSA infections are limited. Linezolid is an antibacterial agent of oxazolidinone group. It has a spectrum limited to gram-positive bacteria. Tigecycline is a broad-spectrum antibiotic of glycylcycline group. A total of 60 MRSA strains isolated from various clinical specimens were included in the study. Minimum inhibitory concentrations (MICs) were determined by Etest method, according to the Clinical and Laboratory Standards Institute (CLSI) and Food and Drug Administration (FDA) criteria. The MIC(90) was 1 microg/ml for linezolid (range 0.094-4 microg/ml), and 0.38 microg/ml for tigecycline (range 0.032-1 microg/ml). All strains were found to be susceptible to linezolid, and only one strain's MIC value was above the threshold for tigecycline. Tigecycline and linezolid may represent therapeutic options for infections caused by MRSA.Keywords
This publication has 21 references indexed in Scilit:
- In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococciInternational Journal of Antimicrobial Agents, 2007
- In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian HospitalsAntimicrobial Agents and Chemotherapy, 2006
- In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002Diagnostic Microbiology and Infectious Disease, 2005
- Linezolid in vitro: mechanism and antibacterial spectrumJournal of Antimicrobial Chemotherapy, 2003
- Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use ProgramClinical Infectious Diseases, 2003
- In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution methodDiagnostic Microbiology and Infectious Disease, 2002
- Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unitPublished by Oxford University Press (OUP) ,2002
- Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.Journal of Antimicrobial Chemotherapy, 2001
- Oxazolidinone antibioticsThe Lancet, 2001
- Antibiotic resistance in staphylococciInternational Journal of Antimicrobial Agents, 2000